Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Top Page
TG Therapeutics
(NASDAQ:TGTX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$40.00
▲(8.99% Upside)
TG Therapeutics' strong revenue growth and strategic product advancements are significant positives. However, high valuation metrics and cash flow challenges present risks. The earnings call provided a positive outlook, but increased expenses and market challenges need monitoring.
Positive Factors
Revenue Growth
Significant revenue growth indicates strong market demand and successful product adoption, enhancing long-term financial stability.
Product Adoption
High adoption rates of BRIUMVI suggest strong competitive positioning and potential for sustained market share in the anti-CD20 segment.
Pipeline Progress
Advancing the pipeline with new trials demonstrates commitment to innovation and potential for future revenue streams from new product formats.
Negative Factors
Increased Operating Expenses
Rising operating expenses could pressure profit margins, requiring careful management to maintain financial health amid growth initiatives.
Cash Flow Challenges
Negative cash flows highlight the need for improved cash management strategies to ensure liquidity and support ongoing operations.
Market Challenges
Shifts towards cost-effective therapies could impact demand for IV treatments, necessitating strategic adjustments to maintain competitiveness.
TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.82B
Dividend YieldN/A
Average Volume (3M)2.07M
Price to Earnings (P/E)98.1
Beta (1Y)1.22
Revenue Growth30.96%
EPS Growth-38.30%
CountryUS
Employees352
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.17
Shares Outstanding158,665,620
10 Day Avg. Volume2,022,175
30 Day Avg. Volume2,065,147
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue12.89
Enterprise Value/Gross Profit14.82
Enterprise Value/Ebitda60.28
Forecast
1Y Price Target
$38.25Price Target Upside4.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
TG Therapeutics Business Overview & Revenue Model
Company DescriptionTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
How the Company Makes MoneyTG Therapeutics generates revenue primarily through the commercialization of its therapeutic products. The company earns money from product sales once its drugs receive regulatory approval and are marketed. Additionally, TG Therapeutics may benefit from milestone payments and royalties from strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide upfront payments, research funding, and share in the revenue generated from successful drug sales. The company is also involved in clinical trials and research collaborations, which can further contribute to its earnings through grants and funding from various health organizations.
TG Therapeutics Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong quarter for TG Therapeutics, marked by significant revenue growth, successful product adoption, and strategic pipeline advancements. However, increased operating expenses and potential market challenges are areas of concern.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenue for Q2 2025 was $141.1 million, including U.S. net product revenue of $138.8 million, representing a 91% increase compared to the same period last year and a 16% growth over the first quarter of this year.
Successful BRIUMVI Adoption
BRIUMVI is now prescribed to nearly 1 in every 3 new IV anti-CD20 patients, with significant growth in patient enrollments and new prescriber accounts.
Commercial Milestones
The company achieved the highest number of new patient enrollments since launch and launched a national television campaign to increase brand awareness.
Pipeline Progress
TG Therapeutics initiated a pivotal Phase III trial for subcutaneous BRIUMVI and dosed the first patient with progressive MS using azer-cel, an investigational CD19-directed CAR-T therapy.
Negative Updates
Increased Operating Expenses
Total operating expenses rose to approximately $71 million for Q2 2025, up from $46.9 million in Q2 of '24, primarily driven by R&D investments and commercial efforts.
Potential Market Challenges
The market for IV therapies is leveling out at about 60-65%, with potential payer push for lower-cost at-home therapies potentially impacting future demand.
Company Guidance
During TG Therapeutics' second quarter 2025 earnings call, the company reported impressive financial and operational performance, primarily driven by the success of its flagship product, BRIUMVI. U.S. net sales for BRIUMVI in Q2 reached approximately $139 million, contributing to total revenue of $141.1 million, which marks a 91% year-over-year increase and a 16% growth from Q1 2025. The company highlighted that nearly 1 in 3 new IV anti-CD20 patients are now prescribed BRIUMVI, and they raised full-year 2025 U.S. net revenue guidance to $575 million. They also outlined strategic efforts to expand BRIUMVI's market reach through the development of a subcutaneous version, aiming to capture 35%-40% of the anti-CD20 market that prefers self-administered options. TG Therapeutics anticipates filing a Biologics License Application (BLA) for subcu BRIUMVI in 2027 and launching in 2028. The company reported GAAP net income of $28.2 million for the quarter, with operating expenses projected to be around $300 million for the full year.TG Therapeutics Financial Statement Overview
Summary
TG Therapeutics shows strong revenue and profit growth with improved balance sheet metrics. However, negative operating cash flow and historical financial instability are concerns.Income Statement
TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.75
Positive
Balance Sheet
The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.65
Positive
Cash Flow
The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 454.07M | 329.00M | 233.66M | 2.79M | 6.69M | 152.00K |
| Gross Profit | 394.85M | 290.52M | 219.11M | 2.52M | 5.90M | 152.00K |
| EBITDA | 97.09M | 49.90M | 26.10M | -187.63M | -341.97M | -272.68M |
| Net Income | 60.46M | 23.38M | 12.67M | -198.34M | -348.10M | -279.38M |
Balance Sheet | ||||||
| Total Assets | 702.61M | 577.69M | 329.59M | 193.57M | 379.63M | 625.64M |
| Cash, Cash Equivalents and Short-Term Investments | 251.87M | 311.00M | 217.51M | 161.68M | 314.76M | 605.43M |
| Total Debt | 253.72M | 254.38M | 110.80M | 83.06M | 79.05M | 41.98M |
| Total Liabilities | 426.18M | 355.33M | 169.09M | 134.99M | 142.48M | 106.29M |
| Stockholders Equity | 276.43M | 222.36M | 160.50M | 58.59M | 237.15M | 519.35M |
Cash Flow | ||||||
| Free Cash Flow | -59.24M | -40.56M | -31.41M | -176.18M | -296.04M | -214.86M |
| Operating Cash Flow | -59.13M | -40.52M | -31.41M | -176.17M | -295.63M | -214.51M |
| Investing Cash Flow | -10.47M | -1.04M | -50.65M | -20.01M | -332.00K | -24.51M |
| Financing Cash Flow | 115.84M | 128.53M | 72.70M | -391.00K | 41.42M | 679.83M |
TG Therapeutics Technical Analysis
Positive
36.70
Price Trends
31.67
Positive
34.10
Positive
34.50
Positive
Market Momentum
1.47
Negative
69.25
Neutral
78.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 36.7 is above the 20-day moving average (MA) of 34.03, above the 50-day MA of 31.67, and above the 200-day MA of 34.50, indicating a bullish trend. The MACD of 1.47 indicates Negative momentum. The RSI at 69.25 is Neutral, neither overbought nor oversold. The STOCH value of 78.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.
TG Therapeutics Risk Analysis
TG Therapeutics disclosed 75 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TG Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $5.82B | 98.09 | 26.63% | ― | 30.96% | -38.30% | |
64 Neutral | $10.90B | -37.34 | -42.46% | ― | 16.04% | 30.61% | |
64 Neutral | $8.32B | -20.67 | -10.92% | ― | 4.52% | -205.13% | |
58 Neutral | $5.99B | -23.72 | -337.87% | ― | 69.83% | 22.16% | |
55 Neutral | $6.46B | -32.80 | -137.04% | ― | 53.55% | 30.87% | |
43 Neutral | $6.05B | -17.18 | ― | ― | ― | -76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TGTX
TG Therapeutics
36.70
15.39
72.22%
IONS
Ionis Pharmaceuticals
69.15
31.29
82.65%
JAZZ
Jazz Pharmaceuticals
139.48
30.96
28.53%
AXSM
Axsome Therapeutics
120.30
36.14
42.94%
RYTM
Rhythm Pharmaceuticals
99.02
51.82
109.79%
NUVL
Nuvalent
84.22
-19.15
-18.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.